EVM
IMVT icon

Eaton Vance Management’s Immunovant IMVT Stock Holding History

Eaton Vance Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-273,138
Closed -$12.6M – 2905
2020
Q4 		$12.6M Sell
273,138
-931
-0.3% -$43K 0.02% 493
2020
Q3 		$9.64M Buy
+274,069
New +$8.24M 0.02% 486

Other funds holding IMVT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Eaton Vance Management's IMVT Position: Q1 2021 in Review

Eaton Vance Management sold out of Immunovant (IMVT) in Q1 2021, closing a stake of 273,138 shares — an estimated $12.6M sold.

Eaton Vance Management first reported a position in IMVT in Q3 2020 and held it in 2 quarters. The position peaked at $12.6M in Q4 2020. 120 funds tracked by Wall St. Rank hold IMVT as of Q1 2021.

  • Eaton Vance Management reported no remaining Immunovant position as of Q1 2021 after selling out during the quarter.
  • Eaton Vance Management sold 273,138 Immunovant shares in Q1 2021, an estimated $12.6M.
  • Eaton Vance Management first reported a position in Immunovant in Q3 2020 and held it in 2 quarters.
  • Eaton Vance Management's Immunovant position peaked at $12.6M in Q4 2020.
  • 120 funds tracked by Wall St. Rank held Immunovant as of Q1 2021.

Based on Eaton Vance Management's 13F filing for Q1 2021, filed 17 May 2021.